10-Q: Femasys Q1 2026 Financial Results and Strategic Update

Femasys reports Q1 2026 net income of $0.85 million, driven by non-cash gains, while maintaining a going concern warning due to liquidity constraints.

Summary

• Reported net income of $0.85 million for Q1 2026, compared to a net loss of $5.90 million in Q1 2025.
• Revenue increased 24.5% year-over-year to $424,889, primarily driven by FemVue sales.
• Operating expenses decreased 21% to $4.49 million, largely due to lower research and development costs.
• Cash and cash equivalents stood at $5.39 million as of March 31, 2026.
• Substantial doubt remains regarding the ability to continue as a going concern for at least one year.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautious report; while the company achieved a net profit, it was primarily due to non-cash accounting adjustments, and the underlying liquidity concerns and going concern warning remain significant risks.

Positives

• Achieved net income of $0.85 million for the quarter.
• Revenue growth of 24.5% compared to the same period in 2025.
• Successful initiation of patient enrollment in the FINALE pivotal clinical trial for FemBloc.
• Reduced total operating expenses by 21% year-over-year.

Negatives

• Net income was significantly bolstered by non-cash gains of $5.2 million from changes in fair value of derivative liabilities, rather than core operational profitability.
• Cash and cash equivalents declined from $9.27 million at year-end 2025 to $5.39 million at March 31, 2026.
• Accumulated deficit remains high at $144.98 million.
• Continued reliance on external financing to fund operations.

Risks

• Substantial doubt exists regarding the ability to continue as a going concern.
• Nasdaq listing compliance risk due to minimum bid price requirements, with a final extension deadline of July 13, 2026.
• Potential for significant dilution to shareholders from future capital raises and warrant exercises.
• Dependence on successful clinical trial outcomes and FDA approval for the FemBloc product candidate.

Future Outlook

The company expects to continue incurring net losses and negative operating cash flows for the foreseeable future as it commercializes products and advances FemBloc through clinical development. Existing cash is expected to fund operations into the third quarter of 2026, necessitating additional capital raises.

Management Comments

• Management emphasizes the importance of the FINALE pivotal clinical trial for FemBloc as a key driver for future growth.
• Management notes the strategic importance of expanding the commercial footprint for FemaSeed and FemBloc internationally and in the U.S.

Industry Context

StockSavvy.ai notes that Femasys operates in a highly competitive and capital-intensive women's health sector. The company's reliance on non-cash accounting gains to report net income highlights the ongoing challenge of achieving operational self-sufficiency in the early-stage medical device market.

Comparison to Industry Standards

• The company's cash burn rate is consistent with early-stage medical device firms focused on clinical trials.
• Revenue levels remain low compared to established women's health players, reflecting the company's early commercialization stage.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings reported.

Related Party Transactions

• Disclosed various financing transactions involving executive officers and directors, including purchases of convertible notes and warrants.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and warrant exercises.
• Employees and creditors are impacted by the company's ongoing liquidity constraints and going concern status.

Next Steps

• Continue enrollment in the FINALE pivotal clinical trial.
• Monitor Nasdaq compliance and potentially execute a reverse stock split.
• Seek additional equity or debt financing to extend operational runway.

Key Dates

Recommendation

The stock is in a high-risk category due to the going concern warning and Nasdaq delisting risk. While the clinical trial progress is positive, the financial instability warrants a hold until the company secures long-term funding or achieves consistent operational cash flow.

Keywords

Femasys, FEMY, FemBloc, FemaSeed, Womens Health, Biomedical, Infertility, SEC Filing, 10-Q